BIBF 1120* in patients with metastatic colorectal cancer as effective as bevacizumab with less serious adverse events

Results from a Phase I/II study among the few to have been selected for presentation in the Presidential Session at the 2011 European Multidisciplinary Cancer Congress (EMCC). - FOR NON-US MEDIA ONLY

Stockholm, Sweden, 27 September, 2011 – Patients with metastatic colorectal cancer (mCRC) receiving BIBF 1120* as first-line treatment in combination with mFOLFOX6 showed a median progression-free survival of 10.6 months which was equivalent to bevacizumab plus mFOLFOX6 in a randomised two arm phase II study enrolling a total of 126 patients. Importantly, only 34.1% of those patients taking BIBF 1120* experienced any kind of serious adverse events, versus 53.7% of those taking bevacizumab.